Breast Cancer

Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.

A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.

The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib.

In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer.

Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events.

Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy.

Trodelvy has impressed a number of key opinion leaders across the breast cancer community based on its results in extending overall survival and progression-free survival in patients with metastatic triple-negative breast cancer who have received ≥2 prior therapies, ≥1 in the metastatic setting. It is becoming a preferred therapy for second-line and later metastatic triple-negative breast cancer treatment.

Compelling efficacy data for sacituzumab govitecan-hziy results in FDA fast-track approval for its use in metastatic triple-negative breast cancer.

Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.

Sacituzumab govitecan-hziy, for the second-line treatment of patients with metastatic triple-negative breast cancer, is a cytotoxic drug that has specific storage, reconstitution, and administration instructions for adherence.